Experts sceptical on Bristol-Myers Squibb’s head and neck cancer trial of Opdivo

Bristol-Myers Squibb’s Phase III first-line head and neck squamous cell carcinoma (HNSCC) trial of Opdivo (nivolumab) and Yervoy (ipilimumab) is being met with scepticism while others said a prior failed trial makes conclusions tough. Credit: Minerva Studio / Shutterstock.



  • Opdivo trial